Slide 1: Conference call First-half 2020 results
Simplifying Progress Conference call First-half 2020 results Joachim Kreuzburg, Rainer Lehmann Sartorius | Sartorius Stedim Biotech July 21, 2020
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 3: H1 2020 highlights
H1 2020 highlights Sales revenue, order intake and earnings with double-digit growth rates Acquisition of selected Danaher life science businesses closed April 30; integration progressing well despite remote mode Bioprocess Solutions Division: Strong growth across all product categories and ge
Slide 4: Agenda
Agenda Sartorius Group H1 2020 results | FY 2020 guidance Sartorius Stedim Biotech Group H1 2020 results | FY 2020 guidance Questions & Answers 4
Slide 5: Dynamic top-line growth; further margin increase
Dynamic top-line growth; further margin increase Sartorius Group H1 2019 H1 2020 in % in % cc1 in millions of € unless otherwise specified Sales revenue 894.7 1,056.8 +18.1 +17.9 Order intake 974.3 1,244.8 +27.8 +27.5 Underlying EBITDA2 237.6 293.5 +23.5 Underlying EBITDA2 margin in % 26.6 27.8 +1.2
Slide 6: Double-digit growth in all geographies
Double-digit growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +19.7 % +16.0 % +18.4% EMEA 419.5 ~ 40% Americas 373.1 362.0 ~ 35% 308.2 264.2 224.5 €1,056.8m H1 2019 H1 2020 H1 2019 H1 2020 H1 2019 H1 2020 Asia|Pacific Americas: Sig
Slide 7: BPS: Strong performance across all product categories and regions
BPS: Strong performance across all product categories and regions Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +33.5% cc +21.3% cc +33.9% +21.6% +29.1% 984.9 735.6 809.3 247.2 665.8 191.5 30.5% 28.8% H1 2019 1 H1 2020 H1 2019 1 H1 2020 H1 2019 1 H1
Slide 8: LPS: Robust sales development
LPS: Robust sales development Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +8.9% cc +8.1% cc +0.4% +8.9% +8.1% 238.8 259.9 46.4 228.9 247.5 46.2 20.2% 18.7% 1 1 H1 2019 H1 2020 H1 2019 H1 2020 H1 2019 1 H1 2020 Difficult economic environment due t
Slide 9: Operating cash flow increases significantly
Operating cash flow increases significantly Sartorius Group H1 2019 H1 2020 in % in millions of € unless otherwise specified Underlying EBITDA 237.6 293.5 +23.5 Net operating cash flow mostly driven by higher earnings and factoring program Extraordinary items -10.6 -26.1 n.m. (~€89m) Financial res
Slide 10: Financial indicators remain robust
Financial indicators remain robust Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Dec. 31, June 30, Sartorius Group 2,000 4.0 2019 2020 1,500 3.0 Equity ratio in % 38.1 30.1 1,000 2.0 Net debt in millions of € 1,014.0 1,669.6 500 1.0 0 0.0 Net debt | underlying 2.0 2.8 Q1-Q4 Q1-
Slide 11: Outlook for 2020 increased for BPS and the Group; uncertainty remains
Outlook for 2020 increased for BPS and the Group; uncertainty remains FY 2020 Guidance1 [change vs. previous guidance] Sales revenue Underlying CAPEX ratio ~10% (FY 2019: 12.3%); net growth EBITDA margin debt to underlying EBITDA slightly below Sartorius Group ~ 22% - 26% [+7pp] ~ 28.5% [+1pp] 2.7
Slide 12: Agenda
Agenda Sartorius Group H1 2020 results | FY 2020 guidance Sartorius Stedim Biotech Group H1 2020 results | FY 2020 guidance Questions & Answers 12
Slide 13: Significant double-digit growth in sales revenue, order intake and profit
Sartorius Stedim Biotech Group Significant double-digit growth in sales revenue, order intake and profit Sartorius Stedim Biotech Group H1 2019 H1 2020 in % in % cc1 in millions of € unless otherwise specified Sales revenue 709.3 869.1 +22.5 +22.0 Order intake 778.1 1,048.7 +34.8 +34.1 Underlying EB
Slide 14: Double-digit growth in all geographies
Sartorius Stedim Biotech Group Double-digit growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +21.9% +18.3% +28.5% EMEA 340.3 ~ 39% Americas 288.0 ~ 36% 312.6 251.8 216.2 €869.1m 169.6 Asia|Pacific H1 2019 H1 2020 H1 2019 H1 2020 H1 2
Slide 15: Operating cash flow rises significantly
Sartorius Stedim Biotech Group Operating cash flow rises significantly Sartorius Stedim Biotech Group H1 2019 H1 2020 in % in millions of € unless otherwise specified Underlying EBITDA 205.3 262.3 +27.8 Net operating cash flow mostly driven by higher earnings and factoring program (~€83m) Extraord
Slide 16: Financial position remains strong
Sartorius Stedim Biotech Group Financial position remains strong Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA 300 1.8 Dec. 31, June 30, Sartorius Stedim Biotech 2019 2020 250 1.5 200 1.2 Equity ratio in % 64.4 57.9 150 0.9 100 0.6 Net debt in millions of € 110.4 243.2 50 0.3 N
Slide 17: Outlook for 2020 increased
Sartorius Stedim Biotech Group Outlook for 2020 increased FY 2020 Guidance1 [change vs. previous guidance] Sales revenue Underlying growth EBITDA margin Sartorius Stedim Biotech ~ 26% - 30% [+9pp] ~ 31.0% [+1pp] - thereof Biological Industries 2pp slightly dilutive - thereof Danaher portfolio 3pp -0
Slide 18: Questions & Answers
Questions & Answers 18
Slide 19: Thank you very much for your attention.
Thank you very much for your attention. 19